Genetic Signatures builds on SARS technology
Shares in Genetic Signatures Limited (ASX:GSS) were up 50% at one stage on Monday morning as management announced that the company had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-2), the virus that causes COVID-19.
Shares in the group started to gain traction in mid-March, increasing from about 90 cents to $1.10 before a Pause in Trading was executed on 26 March in order to for the shares to trade in an informed the market.
Further, the company has submitted a formal application for European CE-IVD registration for a new real time PCR (polymerase chain reaction) assay that does this.
Management has also submitted an application for inclusion on the ARTG (Australian Register of Therapeutic goods).
Confirmation of CE-IVD will allow for the continued marketing and supply throughout Europe and UK, as regulatory exemptions are for a defined period.
Licensed Australian laboratories are permitted to self-validate the tests to use the kits commercially.
The company sells both directly to end users and through distributors in Europe.
European data to support planned FDA emergency use authorisation
Since the beginning of the year when it became apparent the COVID-19 outbreak was a serious global problem, Genetic Signatures has directed resources to develop a SARS-CoV-2 specific test utilising its unique and proprietary 3base technology.
Data has been generated to support the submissions as required by the European IVDD (in vitro diagnostic directive) and TGA Medical Devices Regulation (ARGMD) to allow the product to be marketed as an in vitro diagnostic (IVD) in Australia and Europe.
The data submitted for European approval will also support the planned FDA EUA (Emergency Use Authorisation) regulatory application in the USA in the near term.
CE-IVD marking and inclusion on the ARTG creates a significant opportunity for Genetic Signatures as laboratories and governments seek fast and accurate tests.
The company has introduced laboratories in Europe and Australia for both the new test and its 3base technology and the group has manufacturing in place at its Sydney-based existing manufacturing facilities to meet anticipated initial high-volume orders.
As a global supplier of Covid-19 test kits, Genetic Signatures expects it will be classified as an essential service and, as such will not see its operations unduly impacted by increasingly strict lockdowns.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.